From sequence to scale: Gene editing’s new era in biologics manufacturing

Cell line development serves as the foundational decision in biologics manufacturing, dictating the long-term efficiency and cost-effectiveness of drug production. CHO (Chinese Hamster Ovary) cells remain the industry standard due to their robust growth, regulatory acceptance, and human-like glycosylation patterns. Modern advancements, such as the use of transposases and CRISPR-based tools like CasClover, enable more precise gene integration, significantly increasing titers—from historical benchmarks of 50 milligrams per liter to modern yields reaching 18 grams per liter. By integrating specialized gene editing expertise with GMP manufacturing capabilities, companies can compress development timelines and avoid the inefficiencies of traditional, fragmented outsourcing. This collaborative model ensures that cell lines are optimized for stability and scalability from the outset, ultimately reducing the high costs associated with drug development cycles.